Kimberly Lapham

625 total citations
14 papers, 248 citations indexed

About

Kimberly Lapham is a scholar working on Pharmacology, Molecular Biology and Oncology. According to data from OpenAlex, Kimberly Lapham has authored 14 papers receiving a total of 248 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pharmacology, 6 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Kimberly Lapham's work include Pharmacogenetics and Drug Metabolism (9 papers), Drug Transport and Resistance Mechanisms (6 papers) and Pharmacological Effects and Toxicity Studies (4 papers). Kimberly Lapham is often cited by papers focused on Pharmacogenetics and Drug Metabolism (9 papers), Drug Transport and Resistance Mechanisms (6 papers) and Pharmacological Effects and Toxicity Studies (4 papers). Kimberly Lapham collaborates with scholars based in United States, United Kingdom and Australia. Kimberly Lapham's co-authors include Theunis C. Goosen, Tim F. Ryder, R. Scott Obach, Jonathan Bauman, Ruth Hyland, Robert L. Walsky, Jonathan J. Novak, John O. Miners, Andrew Rowland and Mark Niosi and has published in prestigious journals such as Journal of Medicinal Chemistry, British Journal of Pharmacology and Pharmacology & Therapeutics.

In The Last Decade

Kimberly Lapham

13 papers receiving 237 citations

Peers

Countries citing papers authored by Kimberly Lapham

Since Specialization

Citations

This map shows the geographic impact of Kimberly Lapham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kimberly Lapham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kimberly Lapham more than expected).

Fields of papers citing papers by Kimberly Lapham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kimberly Lapham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kimberly Lapham. The network helps show where Kimberly Lapham may publish in the future.

Co-authorship network of co-authors of Kimberly Lapham

This figure shows the co-authorship network connecting the top 25 collaborators of Kimberly Lapham. A scholar is included among the top collaborators of Kimberly Lapham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kimberly Lapham. Kimberly Lapham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Development of a PBPK Model for Lamotrigine which Incorporates Metabolism by UGT2B10: Impact of UGT2B10 Poor Metabolizer Phenotype and Pregnancy 2025 ·The AAPS Journal ·Iain Gardner, Aki T. Heikkinen, (unknown), Kimberly Lapham, Theunis C. Goosen	1
2	Positioning Enzyme- and Transporter-Based Precipitant Drug–Drug Interaction Studies in Drug Design 2025 ·Journal of Medicinal Chemistry ·Thomas Schroeter, Kimberly Lapham, Manthena V. S. Varma, R. Scott Obach	0
3	Evaluation of Icotinib as a Potent and Selective Inhibitor of Aldehyde Oxidase for Reaction Phenotyping in Human Hepatocytes 2024 ·Drug Metabolism and Disposition ·(unknown), (unknown), Kimberly Lapham, R. Scott Obach	5
4	Clotrimazole Identified as a Selective UGT2B4 Inhibitor Using Canagliflozin-2′-O-Glucuronide Formation as a Selective UGT2B4 Probe Reaction 2024 ·Drug Metabolism and Disposition ·Kimberly Lapham, (unknown), Mark Niosi, Theunis C. Goosen	3
5	UGT2B10 is the Major UDP-Glucuronosyltransferase 2B Isoform Involved in the Metabolism of Lamotrigine and is Implicated in the Drug-Drug Interaction with Valproic Acid 2024 ·The AAPS Journal ·(unknown), Kimberly Lapham, Theunis C. Goosen	7
6	In Vitro Characterization of Ertugliflozin Metabolism by UDP-Glucuronosyltransferase and Cytochrome P450 Enzymes 2020 ·Drug Metabolism and Disposition ·Kimberly Lapham, Ernesto Callegari, Julie Cianfrogna, Jian Lin, Mark Niosi, Christine C. Orozco, Raman Sharma, Theunis C. Goosen	16
7	Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping 2020 ·Pharmacology & Therapeutics ·John O. Miners, Andrew Rowland, Jonathan J. Novak, Kimberly Lapham, Theunis C. Goosen	46
8	6-Chloro-5-[4-(1-Hydroxycyclobutyl)Phenyl]-1H-Indole-3-Carboxylic Acid is a Highly Selective Substrate for Glucuronidation by UGT1A1, Relative to β-Estradiol 2018 ·Drug Metabolism and Disposition ·Kimberly Lapham, Jian Lin, Jonathan J. Novak, Christine C. Orozco, Mark Niosi, Li Di, Theunis C. Goosen, Sangwoo Ryu, Keith Riccardi, Heather Eng, Kimberly O. Cameron, Amit S. Kalgutkar	5
9	Industry standard UGT1A3 probe substrate CDCA: A second look 2018 ·Drug Metabolism and Pharmacokinetics ·Jonathan J. Novak, Jian Lin, Keith Riccardi, Theunis C. Goosen, Kimberly Lapham	1
10	Inhibition of Hepatobiliary Transport Activity by the Antibacterial Agent Fusidic Acid: Insights into Factors Contributing to Conjugated Hyperbilirubinemia/Cholestasis 2016 ·Chemical Research in Toxicology ·Kimberly Lapham, Jonathan J. Novak, Lisa D. Marroquin, Rachel Swiss, (unknown), Christopher J. Strock, Renato J. Scialis, Michael D. Aleo, Thomas Schroeter, Heather Eng, A. David Rodrigues, Amit S. Kalgutkar	9
11	Pharmacological characterization of the first in class clinical candidate PF‐05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose‐dependent insulin secretionex vivo 2016 ·British Journal of Pharmacology ·Jimmy Kong, (unknown), Ingrid A. Stock, Paula M. Loria, Stephen V. Straub, (unknown), Kimberly O. Cameron, Samit K. Bhattacharya, Kimberly Lapham, Kim F. McClure, (unknown), V. Margaret Jackson	23
12	Reactive Metabolite Trapping Studies on Imidazo- and 2-Methylimidazo[2,1-b]thiazole-Based Inverse Agonists of the Ghrelin Receptor 2013 ·Drug Metabolism and Disposition ·Amit S. Kalgutkar, Tim F. Ryder, Gregory S. Walker, Suvi T. M. Orr, Shawn Cabral, Theunis C. Goosen, Kimberly Lapham, Heather Eng	5
13	Optimized Assays for Human UDP-Glucuronosyltransferase (UGT) Activities: Altered Alamethicin Concentration and Utility to Screen for UGT Inhibitors 2012 ·Drug Metabolism and Disposition ·Robert L. Walsky, Jonathan Bauman, (unknown), (unknown), Kimberly Lapham, (unknown), Tim F. Ryder, R. Scott Obach, Ruth Hyland, Theunis C. Goosen	122
14	Insights into the Novel Hydrolytic Mechanism of a Diethyl 2-Phenyl-2-(2-arylacetoxy)methyl Malonate Ester-Based Microsomal Triglyceride Transfer Protein (MTP) Inhibitor 2012 ·Chemical Research in Toxicology ·Tim F. Ryder, Gregory S. Walker, Theunis C. Goosen, Roger B. Ruggeri, Edward L. Conn, Benjamin N. Rocke, Kimberly Lapham, Claire M. Steppan, David Hepworth, Amit S. Kalgutkar	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact